The growing use of immuno-oncology, advancing bioinformatics analysis, and rising investment in precision medicine are driving the immune repertoire sequencing market.
Austin, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) — Immune Repertoire Sequencing Market Growth Analysis:
As per SNS Insider, the Immune Repertoire Sequencing Market was valued at USD 369.93 million in 2025 and is expected to reach USD 837.20 million by 2033, growing at a CAGR of 10.78% during the forecast period of 2026-2033. The Immune Repertoire Sequencing Market is growing due to the rising use of next-generation sequencing technology in the fields of oncology, vaccine development, and autoimmune diseases, along with the constant improvement in bioinformatics tools.
Immune repertoire sequencing is an important tool in the analysis of B-cell receptor and T-cell receptor diversity, which in turn helps in gaining a better understanding of the immune response and the effectiveness of treatments. The increasing need for personalized medicine is also adding to the market momentum.
Get a Sample Report of Immune Repertoire Sequencing Market: https://www.snsinsider.com/sample-request/9227
Immune Repertoire Sequencing Market Size and Forecast:
- Market Size in 2025: USD 369.93 Million
- Market Size by 2033: USD 837.20 Million
- CAGR: 10.78% from 2026 to 2033
- Base Year: 2025
- Forecast Period: 2026–2033
- Historical Data: 2022–2024
U.S. Immune Repertoire Sequencing Market Outlook:
The U.S. Immune Repertoire Sequencing Market is expected to grow from USD 124.17 million in 2025 to USD 265.77 million by 2033, registering a CAGR of 10.01% during the forecast period. The growth of the market is driven by significant investment in immuno-oncology studies, widespread adoption of NGS-based diagnostics, and growing investment in precision medicine programs in top academic institutions, biotech firms, and healthcare institutions.
The incorporation of immune repertoire sequencing in cancer studies and clinical trials is making it possible to stratify patients, monitor treatment, and predict outcomes more accurately, thus solidifying the leadership position of the U.S. market.
Increasing Adoption of Immune Repertoire Profiling in Cancer Immunotherapy Fuels Market Growth:
The increasing adoption of immune repertoire profiling in cancer immunotherapy is a major growth driver for the market. With the growing adoption of precision oncology, there is a rising need for comprehensive BCR and TCR sequencing to track the response to treatment and the evolution of the tumor. There are significant investments being made in immuno-oncology research, and the adoption of sequencing platforms into mainstream cancer care protocols is driving the demand for advanced immune repertoire sequencing platforms.
High Costs and Data Complexity Create Market Challenges:
Despite having bright growth prospects, the high costs of sequencing and the complexity of data interpretation are still hindering the widespread adoption of this technology in the clinical setting. High capital investment in advanced NGS platforms, along with the requirement for sophisticated bioinformatics infrastructure and expertise, is a major cost deterrent for smaller hospitals and research institutions. Moreover, the immune-omics datasets are large and highly complex, leading to increased analysis times and scalability issues.
Major Players Analysis Listed in the Immune Repertoire Sequencing Market Report are
- Illumina
- Thermo Fisher Scientific
- Adaptive Biotechnologies
- BGI Genomics
- 10x Genomics
- QIAGEN
- F. Hoffmann-La Roche
- Takara Bio
- Oxford Nanopore Technologies
- Agilent Technologies
- Pacific Biosciences (PacBio)
- Danaher Corporation
- Azenta Life Sciences
- Personalis
- CD Genomics
- iRepertoire
- Creative Biolabs
- Mission Bio
- ENPICOM
- Dolomite Bio
Need Any Customization Research on Immune Repertoire Sequencing Market, Enquire Now: https://www.snsinsider.com/enquiry/9227
Segmentation Analysis:
By Technology
Next-Generation Sequencing (NGS) held the largest market share of 54.72% in 2025 due to its high-throughput, accuracy and broad-level clinical adoption across segments namely oncology, human leukocyte antigen typing and translational research. Single-Cell Sequencing is expected to grow at the fastest CAGR of 13.97% during 2026–2033 led by need for cell-level immune characterization and deeper repertoire mapping.
By Application
Cancer Research dominated with a 46.81% share in 2025 on account of increasing dependency on immune repertoire sequencing to diagnose immunotherapy results, track tumor evolution, and comprehend patient-specific cellular responses. Vaccine Development is projected to expand at the fastest CAGR of 14.56% during the forecast period driven by health readiness projects and mega-studies to chart new pathogen-specific immune responses.
By Sequencing Type
T-Cell Receptor (TCR) sequencing accounted for the highest market share of 58.30% in 2025 having relevance in immuno-oncology, which helps clinicians to monitor treatment response and administer precision therapies. B-Cell Receptor (BCR) sequencing is anticipated to record the fastest CAGR of 13.34% through 2026–2033, which has found applications in antibody discovery, vaccine optimization, infectious disease response evaluation and others.
By End-User
Pharmaceutical & Biotechnology Companies held the largest share of 41.56% in 2025 driven by strongly investing in immuno-oncology, vaccine development and immune therapy pipelines, which demand sequencing-based biological enablement. Hospitals & Clinics are expected to grow at the fastest CAGR of 13.89% during 2026–2033 due to immune repertoire analysis is emerging in routine diagnostics and treatment monitoring.
Regional Insights:
North America dominated the Immune Repertoire Sequencing Market with 42.78% of the market share, which was largely attributed to its robust adoption of precision medicine, advanced clinical research infrastructure and high investment in immuno-oncology.
The Asia Pacific Immune Repertoire Sequencing Market is the fastest-growing region, projected to expand at a CAGR of 13.18% during 2026–2033. Growth is driven by increasing g investment in genomic medicine, declining cost of sequencing procedure, and the rise in fully integrated single-cell analysis systems and technologies in China, Japan, South Korea, and India.
Purchase Single User PDF of Immune Repertoire Sequencing Market Report (20% Discount): https://www.snsinsider.com/checkout/9227
Recent Developments:
- In July 2025, Illumina launched a new NGS-based proteomics solution enabling faster protein analysis from sample to reporting. The product enhances immune profiling, supports research scalability and strengthens Illumina’s leadership in high-throughput sequencing for oncology and immunology applications.
- In May 2025, Thermo Fisher introduced the Oncomine TCR Beta-SR Assay, expanding its immuno-oncology sequencing portfolio. The assay enhances insights into T-cell receptor diversity, supporting cancer research laboratories adopting precise NGS tools for advanced immune monitoring and analysis.
Exclusive Sections of the Report (The USPs):
- SEQUENCING PERFORMANCE & THROUGHPUT METRICS – assists you in assessing the read depth, coverage, accuracy, runtime efficiency, and sample preparation workflow of immune repertoire sequencing platforms.
- BIOLOGICAL & ANALYTICAL OUTPUT QUALITY INSIGHTS – assists you in evaluating the quality of diversity detection, clonotype resolution, sensitivity to low-abundance clones, and multiplexing capacity based on each sequencing run.
- CLINICAL & RESEARCH UTILITY BENCHMARKS – assists you in comprehending the practical application of the software by monitoring the turnaround times, success rates in diagnostic validation, integration of therapeutic decisions, and implementation in oncology, autoimmune, infectious disease, and vaccine research.
- COST, SCALE & INFRASTRUCTURE EFFICIENCY METRICS – assists you in comparing the cost per sample, usage of instruments, cloud compute usage, and storage needs.
- INNOVATION & TECHNOLOGY READINESS INDICATORS – assists you in recognizing future growth opportunities through the evaluation of patenting, bioinformatics and machine learning implementation, shift to single-cell sequencing, and reporting standardization.
- COMPETITIVE PLATFORM POSITIONING – assists you in estimating the competitiveness of major sequencing and analytics companies in terms of performance capabilities, scalability, clinical utility, and innovation momentum.
Access Complete Report Details of Immune Repertoire Sequencing Market Analysis & Outlook: https://www.snsinsider.com/reports/immune-repertoire-sequencing-market-9227
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.